This article is available to subscribers. Subscribe now. Already have an account? Sign in
Linezolid for Drug-Resistant TuberculosisList of authors.
The development of a highly effective, oral, 6-month regimen for the treatment of multidrug-resistant tuberculosis, which previously took 18 to 24 months to cure, is one of the defining achievements of the tuberculosis research community in this century. The results of the Nix-TB study, which were published in the Journal in 2020,1 showed that the combination of two new drugs, bedaquiline and pretomanid, with a repurposed oxazolidinone antibiotic agent, linezolid, given for 6 to 9 months to patients with drug-resistant or complicated multidrug-resistant tuberculosis, resulted in a favorable outcome in 98 of 109 patients (90%) at 6 months after the . . .
Funding and Disclosures
Disclosure forms provided by the authors are available with the full text of this editorial at NEJM.org.
Print Subscriber? Activate your online access.